EGFR and cancer: Conjugating the anti-EGFR monoclonal antibody nimotuzumab with 27 nm Au NP significantly enhanced therapeutic efficacy against EGFR-overexpressing cancers, as evidenced by lower IC50 values compared to free nimotuzumab [209].